Suppr超能文献

异三聚体 G 蛋白作为药物发现中的治疗靶点。

Heterotrimeric G Proteins as Therapeutic Targets in Drug Discovery.

机构信息

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, 510006 Guangzhou, Guangdong, P. R. China.

Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.

出版信息

J Med Chem. 2020 May 28;63(10):5013-5030. doi: 10.1021/acs.jmedchem.9b01452. Epub 2019 Dec 26.

Abstract

Heterotrimeric G proteins are molecular switches in GPCR signaling pathways and regulate a plethora of physiological and pathological processes. GPCRs are efficient drug targets, and more than 30% of the drugs in use target them. However, selectively targeting an individual GPCR may be undesirable in various multifactorial diseases in which multiple receptors are involved. In addition, abnormal activation or expression of G proteins is frequently associated with diseases. Furthermore, G proteins harboring mutations often result in malignant diseases. Thus, targeting G proteins instead of GPCRs might provide alternative approaches for combating these diseases. In this review, we discuss the biochemistry of heterotrimeric G proteins, describe the G protein-associated diseases, and summarize the currently known modulators that can regulate the activities of G proteins. The outlook for targeting G proteins to treat diverse diseases is also included in this manuscript.

摘要

异三聚体 G 蛋白是 G 蛋白偶联受体信号通路中的分子开关,调节着众多生理和病理过程。G 蛋白偶联受体是高效的药物靶点,超过 30%的现有药物针对它们。然而,在涉及多种受体的各种多因素疾病中,选择性针对单个 G 蛋白偶联受体可能并不理想。此外,G 蛋白的异常激活或表达常与疾病有关。此外,携带有突变的 G 蛋白通常会导致恶性疾病。因此,针对 G 蛋白而不是 G 蛋白偶联受体可能为治疗这些疾病提供了替代方法。在这篇综述中,我们讨论了异三聚体 G 蛋白的生物化学特性,描述了与 G 蛋白相关的疾病,并总结了目前已知可调节 G 蛋白活性的调节剂。本文还包括了针对 G 蛋白治疗各种疾病的前景展望。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验